Do analysts rate PCSA or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PCSA or BFRI more profitable?

Heatwurx has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -394.25% -244.46% Biofrontera -13.78% -145.81% -31.30%

Do analysts recommend PCSA or COCP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, PCSA or COCP?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heatwurx N/A N/A -$13.56M -$4.23 N/A Cocrystal Pharma N/A N/A -$8.83M -$0.76 N/A

Is PCSA or COCP more profitable?

Cocrystal Pharma's return on equity of -207.47% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -394.25% -244.46% Cocrystal Pharma N/A -207.47% -123.33%

Do analysts recommend PCSA or PSTV?

Plus Therapeutics has a consensus price target of $51.75, indicating a potential upside of 1,660.20%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Heatwurx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher valuation & earnings, PCSA or PSTV?

Plus Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heatwurx N/A N/A -$13.56M -$4.23 N/A Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A

Is PCSA or PSTV more profitable?

Heatwurx has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -394.25% -244.46% Plus Therapeutics -230.24% -198.48% -73.13%

Does the media favor PCSA or PSTV?

In the previous week, Heatwurx and Heatwurx both had 1 articles in the media. Heatwurx's average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heatwurx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ABVC or PCSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABVC or PCSA more profitable?

ABVC BioPharma's return on equity of -47.68% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -47.68% -30.97% Heatwurx N/A -394.25% -244.46%

Does the media prefer ABVC or PCSA?

In the previous week, ABVC BioPharma and ABVC BioPharma both had 1 articles in the media. ABVC BioPharma's average media sentiment score of 0.00 equaled Heatwurx'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Heatwurx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PCSA or LEXX?

Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 82.63%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than Heatwurx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PCSA or LEXX more profitable?

Lexaria Bioscience's return on equity of -174.93% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -394.25% -244.46% Lexaria Bioscience N/A -174.93% -143.89%

Does the media refer more to PCSA or LEXX?

In the previous week, Lexaria Bioscience had 1 more articles in the media than Heatwurx. MarketBeat recorded 2 mentions for Lexaria Bioscience and 1 mentions for Heatwurx. Lexaria Bioscience's average media sentiment score of 0.20 beat Heatwurx's score of 0.00 indicating that Lexaria Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heatwurx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lexaria Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Heatwurx (PCSA) Competitors

$2.05 -0.05 (-2.38%)

As of 04:00 PM Eastern

Compare

PCSA vs. BFRI, COCP, PSTV, ABVC, and LEXX

Should you buy Heatwurx stock or one of its competitors? Heatwurx's main competitors and comparable companies include Biofrontera (BFRI), Cocrystal Pharma (COCP), Plus Therapeutics (PSTV), ABVC BioPharma (ABVC), and Lexaria Bioscience (LEXX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Heatwurx compare to Biofrontera?

Heatwurx (NASDAQ:PCSA) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

91.9% of Heatwurx shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 3.5% of Heatwurx shares are held by company insiders. Comparatively, 8.1% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Heatwurx had 1 more articles in the media than Biofrontera. MarketBeat recorded 1 mentions for Heatwurx and 0 mentions for Biofrontera. Heatwurx's average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.

Company	Overall Sentiment
Heatwurx	Neutral
Biofrontera	Neutral

Biofrontera has higher revenue and earnings than Heatwurx. Biofrontera is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
Biofrontera	$41.71M	0.54	-$10.54M	-$0.45	N/A

Heatwurx has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Heatwurx has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
Biofrontera	-13.78%	-145.81%	-31.30%

Summary

Biofrontera beats Heatwurx on 8 of the 13 factors compared between the two stocks.

How does Heatwurx compare to Cocrystal Pharma?

Heatwurx (NASDAQ:PCSA) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cocrystal Pharma's return on equity of -207.47% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
Cocrystal Pharma	N/A	-207.47%	-123.33%

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A

In the previous week, Heatwurx had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 1 mentions for Heatwurx and 0 mentions for Cocrystal Pharma. Heatwurx's average media sentiment score of 0.00 equaled Cocrystal Pharma'saverage media sentiment score.

Company	Overall Sentiment
Heatwurx	Neutral
Cocrystal Pharma	Neutral

Heatwurx has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cocrystal Pharma beats Heatwurx on 6 of the 9 factors compared between the two stocks.

How does Heatwurx compare to Plus Therapeutics?

Heatwurx (NASDAQ:PCSA) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Heatwurx has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Plus Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

In the previous week, Heatwurx and Heatwurx both had 1 articles in the media. Heatwurx's average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heatwurx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Heatwurx has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Plus Therapeutics has a consensus price target of $51.75, indicating a potential upside of 1,660.20%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Plus Therapeutics is more favorable than Heatwurx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Plus Therapeutics beats Heatwurx on 7 of the 12 factors compared between the two stocks.

How does Heatwurx compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Heatwurx (NASDAQ:PCSA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

ABVC BioPharma has higher revenue and earnings than Heatwurx. ABVC BioPharma is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	52.25	-$7.91M	-$0.30	N/A
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A

ABVC BioPharma's return on equity of -47.68% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Heatwurx	N/A	-394.25%	-244.46%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ABVC BioPharma has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Heatwurx has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

In the previous week, ABVC BioPharma and ABVC BioPharma both had 1 articles in the media. ABVC BioPharma's average media sentiment score of 0.00 equaled Heatwurx'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Heatwurx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 3.5% of Heatwurx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ABVC BioPharma beats Heatwurx on 6 of the 9 factors compared between the two stocks.

How does Heatwurx compare to Lexaria Bioscience?

Heatwurx (NASDAQ:PCSA) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Lexaria Bioscience has higher revenue and earnings than Heatwurx. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$4.23	N/A
Lexaria Bioscience	$710K	28.63	-$11.90M	-$5.10	N/A

In the previous week, Lexaria Bioscience had 1 more articles in the media than Heatwurx. MarketBeat recorded 2 mentions for Lexaria Bioscience and 1 mentions for Heatwurx. Lexaria Bioscience's average media sentiment score of 0.20 beat Heatwurx's score of 0.00 indicating that Lexaria Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heatwurx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexaria Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Heatwurx has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 82.63%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than Heatwurx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexaria Bioscience's return on equity of -174.93% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-394.25%	-244.46%
Lexaria Bioscience	N/A	-174.93%	-143.89%

91.9% of Heatwurx shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 3.5% of Heatwurx shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Lexaria Bioscience beats Heatwurx on 10 of the 14 factors compared between the two stocks.

Get Heatwurx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCSA vs. The Competition

Export

Metric	Heatwurx	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.81M	$12.24B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.48	787.27	273.28	25.38
Price / Sales	N/A	753.79	613.48	92.60
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	-18.64	12.33	12.89	6.14
Net Income	-$13.56M	$2.82B	$3.47B	$349.01M
7 Day Performance	-2.84%	1.97%	-0.33%	-1.47%
1 Month Performance	-3.76%	4.87%	6.51%	2.47%
1 Year Performance	-56.31%	9.15%	25.19%	15.84%

Heatwurx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCSA Heatwurx	1.095 of 5 stars	$2.05 -2.4%	N/A	-55.3%	$5.81M	N/A	N/A	20
BFRI Biofrontera	0.981 of 5 stars	$1.59 +6.7%	N/A	+81.0%	$22.13M	$41.71M	N/A	70	Positive News Gap Up
COCP Cocrystal Pharma	1.1821 of 5 stars	$1.10 -3.5%	N/A	-22.7%	$21.96M	N/A	N/A	10	Positive News Gap Up
PSTV Plus Therapeutics	1.8589 of 5 stars	$3.10 +2.6%	$51.75 +1,569.4%	-74.6%	$21.34M	N/A	N/A	20	News Coverage
ABVC ABVC BioPharma	0.3696 of 5 stars	$0.83 +4.3%	N/A	-68.3%	$21.21M	$510K	N/A	30	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCSA) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heatwurx (PCSA) Competitors

PCSA vs. BFRI, COCP, PSTV, ABVC, and LEXX

How does Heatwurx compare to Biofrontera?

Summary

How does Heatwurx compare to Cocrystal Pharma?

Summary

How does Heatwurx compare to Plus Therapeutics?

Summary

How does Heatwurx compare to ABVC BioPharma?

Summary

How does Heatwurx compare to Lexaria Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heatwurx (PCSA) Competitors

PCSA vs. BFRI, COCP, PSTV, ABVC, and LEXX

How does Heatwurx compare to Biofrontera?

Do institutionals & insiders have more ownership in PCSA or BFRI?

Does the media refer more to PCSA or BFRI?

Which has better earnings and valuation, PCSA or BFRI?

Which has more volatility and risk, PCSA or BFRI?

Do analysts rate PCSA or BFRI?

Is PCSA or BFRI more profitable?

Summary

How does Heatwurx compare to Cocrystal Pharma?

Do analysts recommend PCSA or COCP?

Is PCSA or COCP more profitable?

Which has better earnings & valuation, PCSA or COCP?

Does the media favor PCSA or COCP?

Which has more risk and volatility, PCSA or COCP?

Do institutionals & insiders believe in PCSA or COCP?

Summary

How does Heatwurx compare to Plus Therapeutics?

Is PCSA or PSTV more profitable?

Which has higher valuation & earnings, PCSA or PSTV?

Does the media favor PCSA or PSTV?

Which has more volatility and risk, PCSA or PSTV?

Do analysts recommend PCSA or PSTV?

Do insiders & institutionals believe in PCSA or PSTV?

Summary

How does Heatwurx compare to ABVC BioPharma?

Which has higher valuation & earnings, ABVC or PCSA?

Is ABVC or PCSA more profitable?

Do analysts recommend ABVC or PCSA?

Which has more volatility & risk, ABVC or PCSA?

Does the media prefer ABVC or PCSA?

Do insiders and institutionals hold more shares of ABVC or PCSA?

Summary

How does Heatwurx compare to Lexaria Bioscience?

Which has better earnings and valuation, PCSA or LEXX?

Does the media refer more to PCSA or LEXX?

Which has more risk and volatility, PCSA or LEXX?

Do analysts recommend PCSA or LEXX?

Is PCSA or LEXX more profitable?

Do insiders & institutionals hold more shares of PCSA or LEXX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools